EyePoint (EYPT) Short term Debt (2022 - 2023)
EyePoint (EYPT) posted Short term Debt of $5.3 million for Q1 2023, down 49.45% sequentially from $10.5 million in Q4 2022, and down 49.45% YoY from $10.5 million in Q1 2022.
EyePoint (EYPT) Short term Debt (2022 - 2023) Analysis & Trends
EyePoint has reported Short term Debt for 2 years, with the latest figure at $5.3 million in Q1 2023.
- Quarterly Short term Debt fell 49.45% year-over-year to $5.3 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $5.3 million (down 49.45% YoY) and the FY2022 annual result came in at $10.5 million, changed N/A from the prior year.
- Short term Debt fell to $5.3 million in Q1 2023 per EYPT's latest filing, from $10.5 million in the prior quarter.
- Over five years, Short term Debt peaked at $10.5 million in Q1 2022 and troughed at $5.3 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 5.30 Mn |
| Dec 31, 2022 | 10.48 Mn |
| Sep 30, 2022 | 10.48 Mn |
| Jun 30, 2022 | 10.48 Mn |
| Mar 31, 2022 | 10.48 Mn |